'Basis' is an NAD+ supplement by Elysium that has proven to harbor great benefits for one's aging process, focusing on cellular longevity, sleep, and energy levels. NAD+ is also referred to as the "golden nucleotide" as it is one of the most important players in key biological functions.
The product has been developed in collaboration with "the world's leading scientists and research universities" and has shown promising results in a randomized and placebo-controlled clinical trial. The results reveal that patients who took the NAD+ supplement experienced an average of 40% increase in NAD+ levels in one month.
Elysium makes Basis available to audiences on a subscription-based plan as the NAD+ supplement has to be taken over a period of time, in order for the individual to see and feel results.
What's Driving This Trend
- Longevity-focused NAD+ Supplements
- Disruptive innovation opportunity: Develop personalized NAD+ supplements tailored to individual genetic profiles for optimized longevity benefits.
- Cellular Longevity and Anti-aging Products
- Disruptive innovation opportunity: Combine NAD+ supplements with targeted skincare technologies to create anti-aging products that promote cellular longevity.
- Subscription-based Health Supplement Plans
- Disruptive innovation opportunity: Design subscription-based plans for comprehensive health supplements that address various biological functions, including NAD+ support.
Who This Affects Most
- Nutraceuticals
- Disruptive innovation opportunity: Integrate NAD+ supplements with advanced nutraceutical formulations to create targeted products for healthy aging and increased vitality.
- Pharmaceuticals
- Disruptive innovation opportunity: Explore the development of NAD+ analogues or novel delivery systems to enhance the bioavailability and effectiveness of NAD+ supplements.
- Beauty and Wellness
- Disruptive innovation opportunity: Collaborate with cosmetic companies to create beauty and wellness products that incorporate NAD+ supplements for improved anti-aging benefits.
